anmelden
OMX Copenhagen 20
1.539,57
PKT
+38,10
PKT
+2,54
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 11.02.20 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.02.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.02.20 | Novo Nordisk Neutral | UBS AG | |
| 06.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 06.02.20 | Novo Nordisk Outperform | Bernstein Research | |
| 06.02.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.02.20 | A.P. Moeller - Maersk A-S (B) Outperform | Credit Suisse Group | |
| 05.02.20 | Novo Nordisk overweight | Barclays Capital | |
| 05.02.20 | Novo Nordisk Outperform | Bernstein Research | |
| 05.02.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 05.02.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 31.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 29.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 27.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 22.01.20 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 20.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 17.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 17.01.20 | Novo Nordisk Neutral | UBS AG | |
| 17.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 16.01.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.01.20 | Novo Nordisk neutral | Morgan Stanley | |
| 06.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Novo Nordisk kaufen | Bernstein Research | |
| 20.12.19 | A.P. Moeller - Maersk A-S (B) buy | Jefferies & Company Inc. | |
| 19.12.19 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 17.12.19 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 12.12.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.12.19 | Novo Nordisk Neutral | UBS AG | |
| 28.11.19 | A.P. Moeller - Maersk A-S (B) Underweight | JP Morgan Chase & Co. | |
| 27.11.19 | Novo Nordisk Reduce | HSBC | |
| 25.11.19 | A.P. Moeller - Maersk A-S (B) buy | Kepler Cheuvreux | |
| 22.11.19 | A.P. Moeller - Maersk A-S (B) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 21.11.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 21.11.19 | Novo Nordisk Neutral | UBS AG | |
| 21.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.11.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 19.11.19 | A.P. Moeller - Maersk A-S (B) verkaufen | Barclays Capital | |
| 18.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. |